BioTime, Inc.  

(Public, NYSEMKT:BTX)   Watch this stock  
Find more results for NYSEAMEX:BTX
3.12
-0.02 (-0.64%)
Jul 29 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 3.03 - 3.18
52 week 2.00 - 4.10
Open 3.12
Vol / Avg. 876,222.00/281,990.00
Mkt cap 315.88M
P/E     -
Div/yield     -
EPS -0.65
Shares 102.22M
Beta 1.33
Inst. own 37%
Aug 9, 2016
Q2 2016 BioTime Inc Earnings Call - 4:30PM EDT - Add to calendar
Aug 9, 2016
Q2 2016 BioTime Inc Earnings Release - 4:00PM EDT - Add to calendar
Jul 8, 2016
BioTime Inc Annual Shareholders Meeting (Estimated)
Jun 10, 2016
BioTime Inc at Jefferies Healthcare Conference
Jun 9, 2016
BioTime Inc Annual Shareholders Meeting
May 17, 2016
Q1 2016 BioTime Inc Earnings Call
May 10, 2016
Q1 2016 BioTime Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -1157.60% -826.24%
Operating margin -1146.07% -935.32%
EBITD margin - -845.30%
Return on average assets -110.14% -68.57%
Return on average equity -363.70% -158.42%
Employees 133 -
CDP Score - -

Address

1301 Harbor Bay Pkwy
ALAMEDA, CA 94502-2215
United States - Map
+1-510-5213390 (Phone)
+1-510-5213389 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioTime, Inc. is a clinical-stage biotechnology company. The Company is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Company is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company's pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient's own somatic or adult stem cells, at the desired location.

Officers and directors

Alfred D. Kingsley Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
Aditya Mohanty Co-President, Co-Chief Executive Officer, Director
Age: 48
Bio & Compensation  - Reuters
Michael D. West Ph.D. Co-Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Russell L. Skibsted Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Pedro Lichtinger President, Chief Executive Officer of Asterias Biotherapeutics
Age: 60
Bio & Compensation  - Reuters
Judith Segall Vice President - Administration, Corporate Secretary, Director
Age: 61
Bio & Compensation  - Reuters
Michael H. Mulroy Director
Age: 49
Bio & Compensation  - Reuters
Angus Charles Russell Director
Age: 59
Bio & Compensation  - Reuters
Deborah J. Andrews Independent Director
Age: 57
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 49
Bio & Compensation  - Reuters